Ocular Therapeutix (OCUL) Research & Development (2013 - 2026)

Ocular Therapeutix's Research & Development history runs 14 years deep, the most recent figure standing at $66.2 million for Q1 2026.

• In Q1 2026, Research & Development rose 54.5% year-over-year to $66.2 million; the TTM figure through Mar 2026 stood at $220.5 million (up 47.21% YoY), while the FY2025 annual figure was $197.1 million, up 54.42% from the prior year.
• Research & Development was $66.2 million for Q1 2026 at Ocular Therapeutix, up from $50.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $66.2 million in Q1 2026 to a low of $13.1 million in Q1 2022.
• Historically, Research & Development has averaged $29.7 million across 5 years, with a median of $20.7 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Research & Development declined 5.48% in 2022, then jumped 153.1% in 2024.
• A 5-year view of Research & Development shows it stood at $13.5 million in 2022, then gained by 19.58% to $16.2 million in 2023, then surged by 153.1% to $41.0 million in 2024, then increased by 23.94% to $50.8 million in 2025, then surged by 30.34% to $66.2 million in 2026.
• The last three Research & Development figures came in at $66.2 million (Q1 2026), $50.8 million (Q4 2025), and $52.4 million (Q3 2025), per Business Quant data.